Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04091503
Recruitment Status : Not yet recruiting
First Posted : September 16, 2019
Last Update Posted : September 17, 2019
Sponsor:
Information provided by (Responsible Party):
Center Trials & Treatment Europe

Brief Summary:

The purpose of this pilot study is to determine the safety, tolerability, and the maximum tolerated dose intranasal administration of temozolomide (TMZ) as a single agent in Treatment on the patients with GBM.

Intranasal administration is a new method of treating brain tumours for the direct administration of drugs, inhibitors or viruses, with minimal involvement of the BBB. The investigators know the orally prescribed standard chemotherapy temozolomide (TMZ) is widely used to treat glioma tumours.

Received evidence of safety and efficacy in a full cycle of preclinical trials (on GLP Standart) and tests of calculated doses of intranasal administration of TMZ in healthy volunteers.

Intranasal administration of temozolomide is considered as GBM therapy, which provides direct access to a therapeutic dose of the drug into the brain (to the neoplastic process) with low toxicity


Condition or disease Intervention/treatment Phase
Glioma, Malignant Gliosarcoma Astrocytoma of Brain Drug: Intranasal Modified Temozolomide Phase 1

Detailed Description:

The investigators are trying to evaluate a clinically potentially effective intranasal way of delivering TMZ to the brain, taking into account the anatomical structure of os ethmoidal.

The most important factor in the effectiveness of the drug is the achievement of an adequate amount of the active agent in its unbound state with albumin on the blood of a patient and the exposure time to the tumour process. Failure to comply with this requirement (difficulties in overcoming the BBB) was identified as the main obstacle to the successful treatment of all types of brain tumours. Translation to improved clinical outcomes in a patient with GBM has not yet been realized. The investigators will use modified temozolomide (without changing the chemical formula) to exclude as much as possible Anosmia, Hyposmia and other violation of the identification of odours with participants.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Pilot Study to Evaluate the Safety, Tolerability and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma (Phase I)
Estimated Study Start Date : December 10, 2019
Estimated Primary Completion Date : September 15, 2020
Estimated Study Completion Date : November 15, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Intranasal Modified Temozolomide 75 mg/M2 per day
75 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
Drug: Intranasal Modified Temozolomide

Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).

After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated

Other Names:
  • Temozolomide
  • TMZ
  • IM-TMZ

Active Comparator: Intranasal Modified Temozolomide 150 mg/M2 per day
150 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
Drug: Intranasal Modified Temozolomide

Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).

After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated

Other Names:
  • Temozolomide
  • TMZ
  • IM-TMZ

Active Comparator: Intranasal Modified Temozolomide 200 mg/M2 per day
200 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
Drug: Intranasal Modified Temozolomide

Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).

After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated

Other Names:
  • Temozolomide
  • TMZ
  • IM-TMZ




Primary Outcome Measures :
  1. The randomized study to determine the safety of Intranasal Administration of modified Temozolomide. [ Time Frame: up to 60 days (or withdrawal of consent or another discontinuation criterion) from date of randomization ]
    Incidence of Treatment-Emergent Adverse Events will be estimated by the number of participants with Glioblastoma or Gliosarcoma according to the NCI CTC (5.0) with adverse events (AE) in all cohorts.


Secondary Outcome Measures :
  1. The maximum tolerated therapeutic dose (MTD) of modified Temozolomide for intranasal administration [ Time Frame: up to 90 days (or withdrawal of consent or another discontinuation criterion) from date of randomization ]
    In the present study, the maximum dose of modified Temozolomide for intranasal administration is 200 mg / M2 a single daily intranasal administration in a course of 5 days. The frequency of adverse events, unacceptable toxicity, or haematological reactions is estimated on a scale the NCI CTCAE (v. 5.0)


Other Outcome Measures:
  1. Percentage of Participants Alive 6 Months After Start of Treatment of Temozolomide for intranasal administration [ Time Frame: 180 days ]

    Overall survival (OS) will be determined as the time in days from the start of treatment ( randomizations day ) to death due to any cause was estimated by the Kaplan-Meier method.

    If it was not known for certain that the participant to die, time will be censored at the last date the participant with GBM or Gliosarcomawas known to be alive, date of magnetic resonance imaging (MRI), etc, - assessment, which will be defined as the latest among the date of the last visit.


  2. The effectiveness of intranasal administration of modified Temozolomide [ Time Frame: up to 90 days (or withdrawal of consent or another discontinuation criterion) from date of randomization ]
    The effectiveness of the intranasal administration of modified Temozolomide will be evaluated by four MRIs with perfusion (first MRI performed one day before randomization day). The results of all MRI in dynamics will be appreciated by a consultation of radiologists.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent signed
  • 21 years or older
  • Histologically confirmed the diagnosis of Grade 4 astrocytic tumour, which includes glioblastoma, giant cell glioblastoma, gliosarcoma, and glioblastoma with oligodendroglial components
  • The availability of histological material for the possibility of revising histological verification
  • IDH 1 Mutation and IDH2 Mutation are not taken into account when enrolling in that study
  • MGMT promoter methylation MUST BE CONFIRMED
  • Must have a Karnofsky performance status of ≥ 70% and the ability to use intranasal administration
  • Sexually active fertile subjects (male and female) must agree to use accepted methods of contraception during the course of the study and for 3 months after the last intranasal administration of Temozolomide
  • Female subjects of childbearing potential must have a negative pregnancy test at screening.
  • Must be capable of understanding and complying with the protocol requirements

Exclusion Criteria:

  • History of hypersensitivity to TMZ or any of its excipients
  • The subject has had major surgery within 28 days prior to starting study treatment, or had non-water-tight dural closure during previous surgery, or has unhealed wounds from previous surgery
  • The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding.
  • The subject is pregnant or breastfeeding
  • The subject suffered a stroke according to the results of the first MRI upon admission
  • Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (haematological and bone marrow suppression effects), generally at least 3 weeks from the most recent administration (6 weeks for nitrosoureas). Subjects may not have received more than 1 cycle of Irinotecan and Temozolomide as previous relapse therapy
  • Subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04091503


Contacts
Layout table for location contacts
Contact: Silvia Hanton, Dr. +41315207002 trials@e.mail.fr
Contact: Daniel Stoyanov +33367390414 stoyanov@top-email.net

Locations
Layout table for location information
Bosnia and Herzegovina
Central Contact Not yet recruiting
Banja Luka, Bosnia and Herzegovina, 78000
Bulgaria
Central Contact Not yet recruiting
Plovdiv,, Bulgaria, 4004
Georgia
Central Contact
Tbilisi, Georgia, 0008
Sponsors and Collaborators
Center Trials & Treatment Europe

Layout table for additonal information
Responsible Party: Center Trials & Treatment Europe
ClinicalTrials.gov Identifier: NCT04091503     History of Changes
Other Study ID Numbers: 7SQZ309D4W
First Posted: September 16, 2019    Key Record Dates
Last Update Posted: September 17, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Center Trials & Treatment Europe:
TMZ
Temozolomide
Intranasal Administration
Nasal Spray
Intranasal Modified Temozolomide
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Gliosarcoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents